143 related articles for article (PubMed ID: 1557576)
1. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.
Gould AL
Stat Med; 1992 Jan; 11(1):55-66. PubMed ID: 1557576
[TBL] [Abstract][Full Text] [Related]
2. Statistical inference for self-designing clinical trials with a one-sided hypothesis.
Shen Y; Fisher L
Biometrics; 1999 Mar; 55(1):190-7. PubMed ID: 11318154
[TBL] [Abstract][Full Text] [Related]
3. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
4. Sample size determination using an interim analysis.
Bristol DR
J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
[TBL] [Abstract][Full Text] [Related]
5. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a two-stage and three-stage interim-analysis procedure.
Overall JE; Atlas RS
Psychol Rep; 1992 Aug; 71(1):3-14. PubMed ID: 1529071
[TBL] [Abstract][Full Text] [Related]
7. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
8. Planning and revising the sample size for a trial.
Gould AL
Stat Med; 1995 May 15-30; 14(9-10):1039-51; discussion 1053-5. PubMed ID: 7569499
[TBL] [Abstract][Full Text] [Related]
9. Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes.
Shih WJ; Zhao PL
Stat Med; 1997 Sep; 16(17):1913-23. PubMed ID: 9304763
[TBL] [Abstract][Full Text] [Related]
10. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
11. Sample size re-estimation: recent developments and practical considerations.
Gould AL
Stat Med; 2001 Sep 15-30; 20(17-18):2625-43. PubMed ID: 11523073
[TBL] [Abstract][Full Text] [Related]
12. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
13. Self-designing trial combined with classical group sequential monitoring.
Yin G; Shen Y
J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
[TBL] [Abstract][Full Text] [Related]
14. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
Jennison C; Turnbull BW
Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
[TBL] [Abstract][Full Text] [Related]
15. Bayesian predictive approach for inference about proportions.
Lecoutre B; Derzko G; Grouin JM
Stat Med; 1995 May 15-30; 14(9-10):1057-63; discussion 1064. PubMed ID: 7569500
[TBL] [Abstract][Full Text] [Related]
16. An introduction to the use of interim data analyses in clinical trials.
Lewis RJ
Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
[TBL] [Abstract][Full Text] [Related]
17. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
18. Interim analysis: the alpha spending function approach.
DeMets DL; Lan KK
Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
[TBL] [Abstract][Full Text] [Related]
19. Sample size re-estimation for adaptive sequential design in clinical trials.
Gao P; Ware JH; Mehta C
J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
[TBL] [Abstract][Full Text] [Related]
20. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
